Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ALKERMES, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.alkermes.com

Clinical Trials

A Phase 1 Safety Study in Adults With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: ALKS 3831

First Posted Date: 2016-06-17

Last Posted Date: 2016-09-22

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 42

Registration Number: NCT02804568

Locations: 🇺🇸
Alkermes Investigational Site, Dayton, Ohio, United States

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

Phase 3

Completed

Conditions: Opioid Use Disorder

Interventions: Drug: Placebo
Drug: Naltrexone
Drug: Buprenorphine

First Posted Date: 2016-03-02

Last Posted Date: 2019-02-12

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 101

Registration Number: NCT02696434

Locations: 🇺🇸
Segal Institute for Clinical Research, Lauderhill, Florida, United States
🇺🇸
Research Centers of America, LLC, Oakland Park, Florida, United States
🇺🇸
Neuroscience Research Institute, Inc., Winfield, Illinois, United States

and more 6 locations

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: ALKS 3831
Drug: Olanzapine

First Posted Date: 2016-02-29

Last Posted Date: 2020-02-10

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 561

Registration Number: NCT02694328

Locations: 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico

A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: ALKS 3831

First Posted Date: 2016-02-01

Last Posted Date: 2019-07-26

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 281

Registration Number: NCT02669758

Locations: 🇺🇦
Alkermes Investigational Site, Vinnytsia, Ukraine

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

Phase 1

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: Aripiprazole Lauroxil

First Posted Date: 2015-12-22

Last Posted Date: 2016-07-14

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 47

Registration Number: NCT02636842

Locations: 🇺🇸
Alkermes Investigational Site, Marlton, New Jersey, United States
🇺🇸
Alkermes Investigative Site, Dallas, Texas, United States

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: ALK3831
Drug: Placebo
Drug: Olanzapine

First Posted Date: 2015-12-18

Last Posted Date: 2018-06-27

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 403

Registration Number: NCT02634346

Locations: 🇺🇦
Alkermes Investigational Site, Vinnytsia, Ukraine

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Aripiprazole Lauroxil

First Posted Date: 2015-12-18

Last Posted Date: 2018-12-04

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 51

Registration Number: NCT02634320

Locations: 🇺🇸
Alkermes Investigational Site, DeSoto, Texas, United States

A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ALKS 5461

First Posted Date: 2015-09-10

Last Posted Date: 2015-11-10

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 24

Registration Number: NCT02545439

Locations: 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

Phase 3

Completed

Conditions: Opioid Use Disorder

Interventions: Drug: NTX/BUP
Drug: PBO-N/PBO-B
Drug: NTX/PBO-B

First Posted Date: 2015-09-01

Last Posted Date: 2019-03-06

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 380

Registration Number: NCT02537574

Locations: 🇺🇸
North Country Clinical Research, Oceanside, California, United States
🇺🇸
NRC Research Institute, Orange, California, United States
🇺🇸
Atlantic Shores Hospital, Lauderhill, Florida, United States

and more 17 locations

A Water Consumption Study of ALKS 5461 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ALKS 5461

First Posted Date: 2015-08-13

Last Posted Date: 2015-11-10

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 30

Registration Number: NCT02521857

Locations: 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy